ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is SymBio Pharmaceuticals Ltd. ?
1
The company has declared Negative results for the last 10 consecutive quarters
- INTEREST(9M) At JPY 92.25 MM has Grown at inf%
- NET SALES(Q) At JPY 336.84 MM has Fallen at -11.67%
- ROCE(HY) Lowest at -174.65%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -42.41%, its profits have fallen by -26.5%
3
Below par performance in long term as well as near term
- Along with generating -42.41% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is SymBio Pharmaceuticals Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
SymBio Pharmaceuticals Ltd.
-100.0%
-0.35
124.65%
Japan Nikkei 225
70.84%
2.78
25.51%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-15.23%
EBIT Growth (5y)
0.29%
EBIT to Interest (avg)
-451.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0.60
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.63%
ROE (avg)
9.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.53
EV to EBIT
-1.38
EV to EBITDA
-1.38
EV to Capital Employed
16.52
EV to Sales
4.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1196.83%
ROE (Latest)
-369.47%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at JPY -2,330.19 MM
-21What is not working for the Company
INTEREST(9M)
At JPY 92.25 MM has Grown at inf%
NET SALES(Q)
At JPY 336.84 MM has Fallen at -11.67%
ROCE(HY)
Lowest at -174.65%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.37 times
CASH AND EQV(HY)
Lowest at JPY 6,347.25 MM
DEBT-EQUITY RATIO
(HY)
Highest at -70.83 %
Here's what is working for SymBio Pharmaceuticals Ltd.
Net Profit
Higher at JPY -2,330.19 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Here's what is not working for SymBio Pharmaceuticals Ltd.
Interest
At JPY 92.25 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Net Sales
At JPY 336.84 MM has Fallen at -11.67%
over average net sales of the previous four periods of JPY 381.34 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (JPY MM)
Inventory Turnover Ratio
Lowest at 1.37 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Cash and Eqv
Lowest at JPY 6,347.25 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -70.83 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
